We tested 441 clinical strains of anaerobes by using a broth microdilution method to determine the in vitro activity of biapenem for comparison with those of other agents. Biapenem had activity comparable to those of imipenem and meropenem against all groups of anaerobes with MICs for 90%o of the strains tested of 0.06 to 2 ,ug/ml. Against the Bacteroides fragilis group, biapenem was more active than ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin, cefoxitin, cefotaxime, and ceftriaxone. Biapenem was also active against all of the B. capillosus, Prevotella, Clostridium, and Eubacterium strains and anaerobic cocci tested. Against all of the anaerobes tested, biapenem was 32-and 4-fold more active than clindamycin and metronidazole, respectively. These data indicate broad-spectrum activity by biapenem against anaerobes.
The predominant mechanism of ,-lactam resistance among anaerobes is production of ,B-lactamases. Most of the ,B-lactamases studied are characterized as cephalosporinases, particularly among the Bacteroides spp. (12) . However, other anaerobes have 1-lactamases which are characterized as penicillinases (14) . Production of these enzymes is primarily chromosomally mediated, but resistance to cefoxitin by ,3-lactamase production has also been shown to be plasmid mediated and transferable (4) .
Imipenem, a broad-spectrum carbapenem, is highly resistant to most types of 1-lactamases from both aerobes and anaerobes (2) . Two exceptions are type I, chromosomally mediated P-lactamases from aerobic, gram-negative bacilli and the metallo-containing ,B-lactamases of anaerobes (3) . Moreover, in clinical use imipenem must be combined with cilastatin to prevent breakdown of the former by renal dehydropeptidase-I (7, 8) . Biapenem (L-627; LJC 10,627) is a new carbapenem agent that has a structure similar to that of imipenem but differs by the presence of a methyl group in the 1-beta position. Addition of the methyl group confers resistance to the action of dehydropeptidase-I (5). The present study compared the in vitro activity of biapenem with those of imipenem, meropenem, and other agents against clinical isolates of anaerobes. We tested 441 clinical strains of various anaerobes. The test group comprised the following: Bacteroides fragilis group, 339 strains; B. capillosus, 10 strains; Prevotella bivia, 15 strains; P. disiens, 13 strains; Eubacterium spp., 18 strains; Clostridium, spp., 14 strains; Peptostreptococcus spp., 17 strains; Veillonella parvula, 15 strains. Each strain was identified by using selective media, biochemical profiles, and gas-liquid chromatography (6, 15) . ,-Lactamase production was detected by using a nitrocephin assay (Cefinase; BBL Microbiology Systems).
Standard powders for susceptibility testing were provided by the following manufacturers: ampicillin and sulbactam, Pfizer The ampicillin-sulbactam ratio was 2:1. Clavulanate was used at 2 pug/ml. 
